about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyGermline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotypeCurrent Chemotherapy and Potential New Targets in Uterine LeiomyosarcomaRole of cancer-associated fibroblasts in invasion and metastasis of gastric cancerNovel allosteric sites on Ras for lead generationThe distinct conformational dynamics of K-Ras and H-Ras A59GTumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RASSynergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cellsNf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signalingFeedback within the inter-cellular communication and tumorigenesis in carcinomas.Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts.Fast simultaneous detection of K-RAS mutations in colorectal cancer.Inflammation to cancer: The molecular biology in the pancreas (Review).IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.Noonan syndrome: clinical aspects and molecular pathogenesis.Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model.An invertebrate mdm homolog interacts with p53 and is differentially expressed together with p53 and ras in neoplastic Mytilus trossulus haemocytes.Akt1 deletion prevents lung tumorigenesis by mutant K-ras.Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancerSTK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.Present and future evolution of advanced breast cancer therapy.TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling.Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanismsTargeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells.Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesisQuantitative evaluation and reversion analysis of the attractor landscapes of an intracellular regulatory network for colorectal cancer.Chemoenzymatic reversible immobilization and labeling of proteins without prior purification.KRAS promoter oligonucleotide with decoy activity dimerizes into a unique topology consisting of two G-quadruplex unitsRoles of cPLA2alpha and arachidonic acid in cancerInhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.KRAS - An Evolving Cancer Target
P2860
Q21198871-EABA7CB3-0DDE-412A-AC16-4EC5031BA2CAQ24293473-7E96B34E-2EA5-44A8-BF3E-C0143AF94A9DQ26767435-7CF9F4CB-FC99-4B6B-AAB2-C7CCEFD57CF1Q26781520-10BFF0C5-2715-4E4B-8161-DAA29F0E9156Q27317333-4DBD1DCA-EF5B-4D33-88FF-989014DBC606Q27334550-740DF48B-9437-47D1-8E00-36BEE07DC234Q27645826-0F7BD34D-A410-4431-9055-695DA8B88783Q28485464-C25608DC-1B05-4692-B8BC-9109E97DB961Q28592228-2F6F7B10-308A-4C69-B071-B47358BC4F6CQ31061871-7DA880C5-A30F-4907-ABC3-F0CC72734404Q33415058-836F58A0-C54B-43FA-A191-B32B27B73BDEQ33465331-02E93046-2658-43D2-A3C7-0CF43D3BB3A4Q33727657-6DFE3DE4-7462-466E-AF1D-59A4557F23A7Q33776852-368973BE-3A6D-40D5-A7A1-E12C622FF77AQ33806161-A0110135-554E-4F78-928A-78BF97B0BEAFQ33818230-6A379DFD-5B04-4823-9F24-9B38B0DB63BCQ34047836-463D8735-66F4-42F1-BD53-662D6149FC51Q34049042-C0024B52-5552-4FE1-87ED-330177AD22FAQ34128530-D4701536-2352-47E1-80AA-FA8C05CB97B3Q34155946-6C7682DF-375E-4AE2-9771-45A1BA738A36Q34274925-4C91B603-AD48-49BE-9663-D26BDBCB375FQ34344787-50E59754-E1DE-461B-80A4-A27AFBF170E1Q34393409-616B02E3-D41D-456A-AA0C-FF290916A9A8Q34440570-E7CA6F17-296A-4824-95A8-DA4808A4ED4CQ34659415-EF4C0E9A-CD5F-4648-B8ED-5C37578EA8B6Q34687371-1869515D-2A3D-443F-817A-4A1B1622A1EDQ34727214-EEFA1392-6877-41B4-B2A9-D8E072250866Q35083740-7E65A318-E5E7-4E03-A398-BDB5327A3DC6Q35213124-2704D7C1-5541-49C5-87F8-5551B7E9CAF4Q35351594-DB4BD412-4320-439B-B96F-A6BB2886056BQ35584153-63251922-10FC-4398-BF53-6E10F3C1580EQ35888467-36CE9084-48C8-4412-A3F3-662AD20AE5E3Q36007575-8F21374C-EC53-4BCA-AFC5-C9ABF2202EA7Q36337206-3470C7E0-1746-4E29-9D14-24183966046DQ36390395-59295C89-EC92-4BBC-A810-D9417C97AAC3Q36532666-9E65135F-B630-4C3F-8184-722046ABED5AQ36629023-C4F02BA9-6CB9-44E7-B1EB-4637FD715A77Q37087351-3868339C-24BD-4F35-9A67-B0323A51D3DCQ37106945-8AC20D83-FE9C-4418-B02E-1A31208815B2Q37261936-4DD75E48-338E-4B06-8770-EBDD91FA1865
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
K-ras as a target for cancer therapy.
@ast
K-ras as a target for cancer therapy.
@en
type
label
K-ras as a target for cancer therapy.
@ast
K-ras as a target for cancer therapy.
@en
prefLabel
K-ras as a target for cancer therapy.
@ast
K-ras as a target for cancer therapy.
@en
P1476
K-ras as a target for cancer therapy.
@en
P2093
Alex A Adjei
Bret B Friday
P304
P356
10.1016/J.BBCAN.2005.08.001
P407
P577
2005-08-18T00:00:00Z